相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
E. Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
M. Moehler et al.
ANNALS OF ONCOLOGY (2010)
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers
B. F. El-Rayes et al.
ANNALS OF ONCOLOGY (2010)
Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
F. Lordick et al.
BRITISH JOURNAL OF CANCER (2010)
AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)
Y. Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Alberto Bardelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
S. Lorenzen et al.
ANNALS OF ONCOLOGY (2009)
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
Y. -K. Kang et al.
ANNALS OF ONCOLOGY (2009)
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
S-W Han et al.
BRITISH JOURNAL OF CANCER (2009)
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
C. Pinto et al.
BRITISH JOURNAL OF CANCER (2009)
Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era
Anna D. Wagner et al.
CURRENT OPINION IN ONCOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
Bart Jacobs et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial
Desmond Curran et al.
QUALITY OF LIFE RESEARCH (2009)
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
M. Dank et al.
ANNALS OF ONCOLOGY (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab
Markus Moehler et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients
Eva Lieto et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy?
Daniel Drescher et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2007)
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
C. Pinto et al.
ANNALS OF ONCOLOGY (2007)
Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray
Huachuan Zheng et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
Multimodal treatment of gastric cancer
Markus Moehler et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2007)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
Anna D. Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer
M Moehler et al.
BRITISH JOURNAL OF CANCER (2005)
Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1α
RJ Phillips et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression
RB Luwor et al.
ONCOGENE (2005)
Mutations of PIK3CA in gastric adenocarcinoma -: art. no. 29
VSW Li et al.
BMC CANCER (2005)
Trends in mortality from major cancers in the European Union, including acceding countries, in 2004
F Levi et al.
CANCER (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability
W Zhao et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
BRAF and KRAS mutations in stomach cancer
SH Lee et al.
ONCOGENE (2003)
Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer
I García et al.
ANNALS OF SURGICAL ONCOLOGY (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Common toxicity criteria: Version 2.0. an improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy
A Trotti et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
